Health · Science · Tech Edition
For founders who need traction without compromising scientific integrity.
Curated by Mark Stinson · Venture Catalyst System™ — Health · Science · Tech edition
Mark Stinson
Exact Rush · Venture Catalyst System™
The Health · Science · Tech edition adds evidence-tier discipline to the Venture Catalyst System™. Mark Stinson built this edition after watching science-led founders either dumb down their work for marketing or oversell early data and lose credibility with investors, regulators, and clinicians.
These agents tag every claim by evidence strength. They map regulatory pathways before copy is written. They build KOL relationships before you need a quote. And they structure investor materials around milestones, not hype. The result is a GTM system that earns trust instead of spending it.
Mark Stinson
Curator, Marketing Suite
15+ years of founder-first brand consulting. Mark built the Venture Catalyst System™ to prevent the mistake he sees most often: founders jumping to design before they know what they are trying to say.
Venture Catalyst System™
What's Included
- ✓Venture Catalyst Orchestrator (Dr. Vivian Strauss) + 6 specialist agent files
- ✓Living project dossier template (evidence-tier fields)
- ✓Getting-started guide with regulatory-pathway checklist
- ✓Sample outputs: pitch deck, KOL outreach, publication plan
- ✓Evidence-tier framework embedded in every agent
- ✓Future updates to the Health · Science · Tech edition
Get Health · Science · Tech Edition
Not a subscription. Plan 4–6 weeks active work.
Secure PayPal checkout · Digital download · Lifetime updates for this edition
Evidence-Tier System
Every claim generated by the suite is tagged so stakeholders know exactly what stands behind it.
| Tag | Meaning | Example |
|---|---|---|
| [EV:STUDY] | Peer-reviewed or published clinical/data | RCT, pivotal trial |
| [EV:MECHANISM] | Established mechanism | Validated pathway, cleared device mechanism |
| [EV:HYPOTHESIS] | Reasoned, not yet proven at scale | Preliminary data |
Who it's for
- ✓Biotech founders preparing for Series A with real data
- ✓Health-tech companies navigating FDA pre-submission
- ✓Med-tech teams who need KOL engagement before launch
- ✓Science-led SaaS selling to regulated industries
Meet the Seven Agents
Each agent has one job. Each job is essential. Vivian runs first.
Venture Catalyst Orchestrator
Dr. Vivian Strauss
Vivian coordinated brand and commercialization teams for fifteen years. She prevents the classic science-founder mistake: beautiful identity on an incoherent value proposition. Sequence is credibility.
Venture Brand Strategist
Dr. James Okonkwo
James started as a medical writer. He knows your mechanism is real — and that investors hear noise unless positioning translates it. The Venture Brand Brief is stakeholder-ready specificity.
Creative Director & Copywriter
Helena Morales
Helena architects narrative by audience without changing the science. Pitch deck, website, founder voice — each version defensible, each labeled.
Logo & Identity Designer
Priya Sharma
Priya builds identity systems that signal rigor in health-tech, biotech, and med-tech — not generic "DNA helix" branding unless your story demands it.
Social Media Manager
Alex Rivera
Alex designs founder-led credibility on LinkedIn and compliant social frameworks — thought leadership that demonstrates understanding, not product spam.
Medical Thought-Leader Researcher
Dr. Anika Mehta
Anika maps KOLs, competitive claims, and evidence gaps. Every assertion gets a tier or gets revised.
Patient & Consumer Market Research Manager
Rachel Xu
Rachel turns patient and buyer voices into objection maps and message tests — the human layer investors ask for in diligence.
Ready to deploy
$799 one-time · Plan 4–6 weeks of active work
Secure PayPal checkout · Digital download · Lifetime updates for this edition
Common Questions
How do the evidence tiers work in practice?
Every claim generated by the suite is tagged with an evidence tier: [EV:STUDY] for peer-reviewed or clinical data, [EV:MECHANISM] for known biological or technical pathways, and [EV:HYPOTHESIS] for early-stage or exploratory assertions. This lets stakeholders instantly see what is proven, what is plausible, and what is speculative. No claim goes to market without its tier label.
Can this help with FDA communications?
Yes. The suite maps your device or therapeutic pathway, identifies pre-approval communication guardrails, and designs messaging frameworks that stay compliant while still building market awareness. It does not replace legal counsel, but it ensures your marketing team knows the boundaries before copy is written.
What about pitch decks for investors?
Helena Morales builds investor materials that lead with evidence tiers, not hype. She structures the narrative around clinical or technical milestones, competitive positioning, and regulatory path. The result is a deck that respects investor diligence and does not oversell early-stage data.
How is this different from hiring a medical writer?
A medical writer produces documents. The Health · Science · Tech suite produces strategy, sequencing, and a system that keeps producing. The living dossier ensures that every piece of content — from a tweet to a regulatory submission — references the same evidence base and uses the same tier labels. It is a methodology, not a one-off deliverable.
What is KOL profiling?
Key Opinion Leader profiling identifies the researchers, clinicians, and advisors who shape thinking in your therapeutic area or technical domain. Dr. Anika Mehta maps their publication history, conference activity, and collaboration networks, then sequences outreach to build authentic relationships before you need anything from them.
Marketing Suite editions curated by Mark Stinson for Exact Rush, distributed on ProvenanceAI Marketing Black Box, Venture Catalyst System™.